Developing a Gene Therapy with Transformative Potential for Patients with Recessive Dystrophic Epidermolysis Bullosa – Drug Discovery & Development
Drug Discovery & Development |
Developing a Gene Therapy with Transformative Potential for Patients with Recessive Dystrophic Epidermolysis Bullosa
Drug Discovery & Development The term “butterfly children” sounds pleasant but refers to a harsh reality: children with epidermolysis bullosa, or EB, an inherited, genetic blistering skin disorder, are born with skin as fragile as a butterfly’s wings. EB affects all races … |
Drug Discovery & Development |
Developing a Gene Therapy with Transformative Potential for Patients with Recessive Dystrophic Epidermolysis Bullosa
Drug Discovery & Development The term “butterfly children” sounds pleasant but refers to a harsh reality: children with epidermolysis bullosa, or EB, an inherited, genetic blistering skin disorder, are born with skin as fragile as a butterfly’s wings. EB affects all races … |
Drug Discovery & Development |
Developing a Gene Therapy with Transformative Potential for Patients with Recessive Dystrophic Epidermolysis Bullosa
Drug Discovery & Development The term “butterfly children” sounds pleasant but refers to a harsh reality: children with epidermolysis bullosa, or EB, an inherited, genetic blistering skin disorder, are born with skin as fragile as a butterfly’s wings. EB affects all races … |
|
Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel’s …
Nasdaq Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that the results from the first clinical study of ilixadencel in patients with … |
Proactive Investors USA & Canada |
Cynata Therapeutics achieves progress in stem cell technology
Proactive Investors USA & Canada Cynata Therapeutics (ASX:CYP) has received the Notice of Allowance from the U.S. patent office for a patent application tied to its proprietary Cymerus™ stem cell technology. This patent application covers an important element of Cynata’s stem cell … |